Psoriasis Clinical Trial
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Summary
This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).
Full Description
The study consists of a 48-week double-blind Treatment Period, an optional 96-week open-label extension (OLE) Period and an optional 48-week OLE2 Period for eligible subjects in the USA and Canada.
Eligibility Criteria
Inclusion Criteria:
Double-blind Treatment Period
Male or female at least 18 years of age
Subject must have had chronic plaque psoriasis (PSO) for at least 6 months prior to the Screening visit
Subject must have Psoriasis Area Severity Index (PASI) >=12 and body surface area (BSA) affected by PSO >=10% and Investigator's Global Assessment (IGA) score >=3 on a 5 point scale
Subject must be a candidate for systemic PSO therapy and/or phototherapy
Subject must be considered, in the opinion of the Investigator, to be a suitable candidate for treatment with secukinumab per regional labeling and has no contraindications to receive secukinumab as per the local label
Female subject of childbearing potential must be willing to use highly effective method of contraception
Open-label extension (OLE) Period
Completed the double-blind Treatment Period without meeting any withdrawal criteria
All Week 48 visit assessments completed
Compliant with ongoing clinical study requirements
Signed a separate OLE Period Informed Consent Form (ICF)
Female subject of childbearing potential must be willing to use highly effective method of contraception
OLE2 Period (USA and Canada)
Completed the OLE Period without meeting any withdrawal criteria
Compliant with ongoing clinical study requirements
Female subject of childbearing potential must be willing to use highly effective method of contraception
Subjects with a diagnosis of Crohn's disease or ulcerative colitis are allowed as long as they have no active symptomatic disease (US only)
Signed a separate OLE2 Period ICF
Exclusion Criteria:
Double-blind Treatment Period
Subject has an active infection (except common cold), a serious infection, or a history of opportunistic, recurrent or chronic infections
Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection
Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection
Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study
Presence of active suicidal ideation or severe depression
Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer
OLE2 Period (USA and Canada)
Subject has developed any medical or psychiatric condition, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in OLE2 Period
Subject had a positive or indeterminate interferon-gamma release assay (IGRA) in the OLE study to Week 144, unless appropriately evaluated and treated
Presence of active suicidal ideation or severe depression
Subject has developed any active malignancy or history of malignancy prior to the OLE2 Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 25 Locations for this study
Santa Ana California, 92701, United States
Danbury Connecticut, 06810, United States
Ocala Florida, 34470, United States
Ormond Beach Florida, 32174, United States
Pembroke Pines Florida, 33028, United States
Tampa Florida, 33613, United States
Tampa Florida, 33614, United States
West Palm Beach Florida, 33409, United States
Sandy Springs Georgia, 30329, United States
Skokie Illinois, 60077, United States
West Dundee Illinois, 60118, United States
West Des Moines Iowa, 50265, United States
New Orleans Louisiana, 70115, United States
Clayton Missouri, 63105, United States
Saint Louis Missouri, 63141, United States
Portsmouth New Hampshire, 03801, United States
Kew Gardens New York, 11415, United States
High Point North Carolina, 27262, United States
Wilmington North Carolina, 28405, United States
Bexley Ohio, 43209, United States
Portland Oregon, 97210, United States
Portland Oregon, 97223, United States
Dallas Texas, 75246, United States
Houston Texas, 77004, United States
Pflugerville Texas, 78660, United States
Carlton , , Australia
Hectorville , , Australia
Kogarah , , Australia
Parkville , , Australia
Woolloongabba , , Australia
Brussels , , Belgium
Bruxelles , , Belgium
Liege , , Belgium
Halifax , , Canada
Hamilton , , Canada
Mississauga , , Canada
Peterborough , , Canada
Richmond Hill , , Canada
Toronto , , Canada
Waterloo , , Canada
Toulouse , , France
Augsburg , , Germany
Berlin , , Germany
Hamburg , , Germany
Lübeck , , Germany
Mahlow , , Germany
Mainz , , Germany
München , , Germany
Münster , , Germany
Neu-ulm , , Germany
Tuebingen , , Germany
Witten , , Germany
Amsterdam , , Netherlands
Breda , , Netherlands
Bialystok , , Poland
Bialystok , , Poland
Bialystok , , Poland
Gdansk , , Poland
Katowice , , Poland
Katowice , , Poland
Krakow , , Poland
Krakow , , Poland
Lodz , , Poland
Ostrowiec Swietokrzyski , , Poland
Wroclaw , , Poland
Wroclaw , , Poland
Alicante , , Spain
Barcelona , , Spain
Madrid , , Spain
Madrid , , Spain
Madrid , , Spain
Sant Joan Despí , , Spain
Gaziantep , , Turkey
Istanbul , , Turkey
Kayseri , , Turkey
Newcastle Upon Tyne , , United Kingdom
Salford , , United Kingdom
How clear is this clinincal trial information?